Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957653 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL7779858 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL955673 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL7782669 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL957475 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL6656018 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL953592 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL956942 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL536268 | 1.00 | LMNA (0.38) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL835510 | 0.97 | LMNA (0.33) | LMNATHRBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | claimed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | claimed |
| EP-1075461-B1 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | SIGMA TAU IND FARMACEUTI (IT) | 2004-07-28 | — | — | EP | claimed |
| US-6476243-B1 | Perfluorinated esters of alkanoyl L-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-11-05 | — | — | US | claimed |
| EP-1075461-A2 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-02-14 | — | — | EP | claimed |
| WO-1999057094-A2 | PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-11-11 | — | — | WO | claimed |
| WO-2024145662-A1 | 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS | ALTAY THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11976163-B2 | Carbonate-linked surface modifying macromolecules | Evonik Canada Inc. (CA) | 2024-05-07 | — | — | US | disclosed |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | HOLOSMEDIC (KR) | 2024-03-28 | — | — | US | disclosed |
| CN-117586659-A | Antibacterial adherent surfaces | 赢创加拿大公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3455269-B1 | IMPLANTABLE GLUCOSE SENSORS HAVING A BIOSTABLE SURFACE | EVONIK CANADA INC (CA) | 2023-09-20 | — | — | EP | disclosed |
| EP-0589949-A1 | NEW PEPTIDES (DIDEMNINS), THEIR PREPARATION AND THEIR USE. | BASF AG (DE) | 1994-04-06 | — | — | EP | disclosed |
| WO-1993000362-A1 | NEW PEPTIDES (DIDEMNINS), THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1993-01-07 | — | — | WO | disclosed |
| US-4108631-A | HERBICIDES, INSECTICIDES | ELI LILLY AND COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-RE29508-E | HERBICIDES AND INSECTICIDES | ELI LILLY AND COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4011341-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
| US-3989840-A | Control of animal parasites with ring-substituted N-(2,2-difluoroalkanoyl)-O-phenylenediamines | ELI LILLY AND COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
| US-3962263-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976163-B2 | Carbonate-linked surface modifying macromolecules | EPCAM, CD44, F12 | LMNA 223/4885THRB 2949/4885CA2 100/4885 |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | LMNA 1536/4885THRB 917/4885CA2 2550/4885 |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | SLC11A2, ABCC1, TSG101 | LMNA 2799/4885THRB 4268/4885CA2 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.